Zenas Biopharma, Common Etf Probability of Future Etf Price Finishing Over 9.25
| ZBIO Etf | USD 9.25 0.09 0.98% |
Zenas |
Zenas BioPharma, Target Price Odds to finish over 9.25
The tendency of Zenas Etf price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 9.25 | 90 days | 9.25 | roughly 97.0 |
Based on a normal probability distribution, the odds of Zenas BioPharma, to move above the current price in 90 days from now is roughly 97.0 (This Zenas BioPharma, Common probability density function shows the probability of Zenas Etf to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Zenas BioPharma, has a beta of 0.27. This usually means as returns on the market go up, Zenas BioPharma, average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Zenas BioPharma, Common will be expected to be much smaller as well. Additionally Zenas BioPharma, Common has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Zenas BioPharma, Price Density |
| Price |
Predictive Modules for Zenas BioPharma,
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Zenas BioPharma, Common. Regardless of method or technology, however, to accurately forecast the etf market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the etf market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Zenas BioPharma, Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Zenas BioPharma, is not an exception. The market had few large corrections towards the Zenas BioPharma,'s value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Zenas BioPharma, Common, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Zenas BioPharma, within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.91 | |
β | Beta against Dow Jones | 0.27 | |
σ | Overall volatility | 4.26 | |
Ir | Information ratio | -0.17 |
Zenas BioPharma, Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Zenas BioPharma, for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Zenas BioPharma, Common can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Zenas BioPharma, generated a negative expected return over the last 90 days | |
| Zenas BioPharma, has high historical volatility and very poor performance | |
| Zenas BioPharma, has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (37.12 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| The fund created three year return of -33.0% | |
| Latest headline from investing.com: Zenas BioPharma CEO Leon O. Moulder Jr. purchases 718,100 in stock | |
| Zenas BioPharma, Common keeps most of the net assets in exotic instruments. |
Zenas BioPharma, Technical Analysis
Zenas BioPharma,'s future price can be derived by breaking down and analyzing its technical indicators over time. Zenas Etf technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Zenas BioPharma, Common. In general, you should focus on analyzing Zenas Etf price patterns and their correlations with different microeconomic environments and drivers.
Zenas BioPharma, Predictive Forecast Models
Zenas BioPharma,'s time-series forecasting models is one of many Zenas BioPharma,'s etf analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Zenas BioPharma,'s historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the etf market movement and maximize returns from investment trading.
Things to note about Zenas BioPharma, Common
Checking the ongoing alerts about Zenas BioPharma, for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Zenas BioPharma, Common help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Zenas BioPharma, generated a negative expected return over the last 90 days | |
| Zenas BioPharma, has high historical volatility and very poor performance | |
| Zenas BioPharma, has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (37.12 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| The fund created three year return of -33.0% | |
| Latest headline from investing.com: Zenas BioPharma CEO Leon O. Moulder Jr. purchases 718,100 in stock | |
| Zenas BioPharma, Common keeps most of the net assets in exotic instruments. |
Other Information on Investing in Zenas Etf
Zenas BioPharma, financial ratios help investors to determine whether Zenas Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zenas with respect to the benefits of owning Zenas BioPharma, security.